Condition (MeSH)
Nevus
ClinicalTrials.gov lists 84 trials for Nevus or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
43 of the 84 trials are tagged with Nevus itself; the rest are tagged with a narrower condition beneath it.
When did Nevus trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 5 |
| 2024 | 3 |
| 2023 | 4 |
| 2022 | 8 |
| 2021 | 3 |
| 2020 | 6 |
| 2019 | 5 |
| 2018 | 5 |
| 2017 | 2 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 4.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 31 months across 49 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Nevus trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 3 |
| Phase 2 | 6 |
| Phase 3 | 2 |
| Phase 4 | 1 |
| Not applicable | 16 |
| Observational | 50 |
How many Nevus trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 5 |
| Recruiting | 13 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 2 |
| Completed | 46 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Nevus trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 4 |
| Orlucent, Inc | 4 |
| AI Labs Group S.L | 2 |
Which drugs are being tested for Nevus? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Burosumab | 3 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Samples | 2 |
| B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state) | 1 |
| Lumbar puncture | 1 |
| Single agent, adjuvant anti-PD1 therapy | 1 |
| data collection | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Nevus trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neoplasm Progression | 4 | 1 |
| Acute Respiratory Failure | 2 | 1 |
| Cardiac Arrest | 2 | 1 |
| Acute Kidney Injury | 1 | 1 |
| Ascites | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Nevus? (43)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| BioMEL: a translational research biobank of melanocytic lesions and melanoma. | BMJ open | 2024 | Yes |
| Diagnostic performance of augmented intelligence with 2D and 3D total body photography and convolutional neural networks in a high-risk population for melanoma under real-world conditions: A new era of skin cancer screening? | European journal of cancer (Oxford, England : 1990) | 2023 | Yes |
| Melanoma classification using light-Fields with morlet scattering transform and CNN: Surface depth as a valuable tool to increase detection rate. | Medical image analysis | 2022 | Yes |
| Treatment of Becker's nevus with 577-nm pro-yellow laser: Could it be a new treatment choice? | Journal of cosmetic dermatology | 2021 | Yes |
| Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome. | American journal of human genetics | 2019 | Yes |
Showing 5 of 43 publications.
Sub-conditions in MeSH (4)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.